NVS - Novartis AG

NYSE - Nasdaq Real Time Price. Currency in USD
88.13
+0.38 (+0.43%)
As of 2:32PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close87.75
Open88.25
Bid88.07 x 1100
Ask88.04 x 1400
Day's Range87.60 - 88.47
52 Week Range72.30 - 94.19
Volume2,892,496
Avg. Volume2,290,357
Market Cap203.572B
Beta (3Y Monthly)0.85
PE Ratio (TTM)15.44
EPS (TTM)5.71
Earnings DateN/A
Forward Dividend & Yield2.98 (3.34%)
Ex-Dividend Date2018-03-06
1y Target Est98.50
Trade prices are not sourced from all markets
  • Health Care Digest: Chelsea Clinton's shout out, Verily shelves 'smart lens' for diabetes, an East Bay biotech's hunt for employees and more
    American City Business Journals4 hours ago

    Health Care Digest: Chelsea Clinton's shout out, Verily shelves 'smart lens' for diabetes, an East Bay biotech's hunt for employees and more

    Clover Health's flu shot-monitoring report was praised by Clinton — part of our weekly Health Care Digest roundup.

  • Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs
    Zacks5 hours ago

    Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs

    Per a Wall Street report, Pfizer (PFE) plans to increase the list prices of its 41 prescription drugs in 2019.

  • Benzinga4 hours ago

    Novartis Is Set For 'Higher Returns And Growth,' Goldman Sachs Says In Upgrade

    Novartis AG (NYSE: NVS ) has been on a tear since hitting a year-over-year nadir in June. As the drugmaker rides positive partnerships, drug approvals and trial successes, one analyst is projecting good ...

  • The Wall Street Journal7 hours ago

    [$$] Novartis CEO Bets on Cutting-Edge Science to Remake Drug Giant

    AG’s recent acquisition streak is pivoting the company toward new treatments that bear little resemblance to traditional drugs. The Swiss company has spent nearly $15 billion in the past year to build its presence in cutting-edge areas of medical research, including gene therapy, or treatments that introduce new DNA into the body, and radiopharmaceuticals, which are drugs that carry radioactive particles to tumors for close-range radiotherapy. ’s ambition to get ahead on innovative therapies that he believes will drive significant future growth.

  • Reuters3 days ago

    Novartis' blood disorder drug gets FDA approval for expanded use

    Novartis AG said on Friday the U.S. Food and Drug Administration expanded the use of its low platelets drug to treat patients with a rare, genetic blood disorder. The drug, Promacta, received the green light as a combination with standard immunosuppressive therapy to treat patients two years and older suffering from treatment-resistant severe aplastic anemia (SAA). SAA is a blood disorder in which a patient's bone marrow fails to produce enough red blood cells, white blood cells and platelets.

  • Reuters3 days ago

    Alphabet unit halts glucose-detecting contact lens project

    Alphabet Inc's life sciences division Verily said on Friday that it was putting on hold one of its oldest and highest-profile projects, a smart contact lens designed to help monitor sugar levels. The project, started in 2014, aimed to help diabetics better manage their blood sugar levels by embedding sensors on a contact lens to monitor the glucose levels in their tears. In a blog update, Verily cited https://blog.verily.com/2018/11/update-on-our-smart-lens-program-with.html insufficient consistency in the correlation between tear glucose and blood glucose concentrations to support the requirements of a medical device.

  • How Bausch + Lomb/International Performed
    Market Realist3 days ago

    How Bausch + Lomb/International Performed

    Bausch + Lomb/International is a wholly owned subsidiary of Bausch Health Companies (BHC). Bausch + Lomb/International generated revenues of $1.1 billion in the third quarter of this year compared to $1.2 billion in the third quarter of 2017, reflecting a ~7% YoY decline. However, Bausch + Lomb/International witnessed ~3% organic revenue growth.

  • Reuters4 days ago

    Novartis launches third-to-market Remicade copy in Germany

    Novartis launched a copy of Johnson & Johnson's (J&J) inflammation-fighting Remicade in Germany on Thursday as the Swiss drugmaker aims to catch rival biosimilars that are already available in Europe's largest healthcare market. Novartis's Sandoz generics unit in May won European approval for Zessly, known generically as infliximab.

  • The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere
    Zacks4 days ago

    The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere

    The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere

  • Reuters4 days ago

    Novartis 'completely committed' to Sandoz, has no split-off plan

    Swiss drugmaker Novartis (NOVN.S) is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off. "We're completely committed to the Sandoz business, and we're looking at transforming it and making it as strong as it can be in the global generics business," Novartis spokesman Sreejit Mohan told Reuters. Earlier, Swiss newspaper Tages-Anzeiger reported the Basel-based drugmaker was preparing to split off Sandoz, citing an employee representative as well as participants in a Novartis investor event last week in London.

  • Reuters4 days ago

    Novartis 'completely committed' to Sandoz, has no split-off plan

    Swiss drugmaker Novartis is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan planned to split the unit off. "We're completely committed to the Sandoz business, and we're looking at transforming it and making it as strong as it can be in the global generics business," Novartis spokesman Sreejit Mohan told Reuters.

  • Reuters4 days ago

    Novartis says 'completely committed' to Sandoz, not planning split-off

    Swiss drugmaker Novartis is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan ...

  • Migraine-Focused Biotech Has A Headache On Quarterly Losses
    Investor's Business Daily5 days ago

    Migraine-Focused Biotech Has A Headache On Quarterly Losses

    Biohaven Pharmaceutical slumped to a three-week low Wednesday after the biotech reported greater-than-expected third-quarter losses.

  • Novartis AG (NVS) Not Doing Enough to Attract Smart Money
    Insider Monkey5 days ago

    Novartis AG (NVS) Not Doing Enough to Attract Smart Money

    Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. The NASDAQ and Russell 2000 indices are already in correction territory. More importantly, the Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in October. Hedge […]

  • Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
    Market Realist6 days ago

    Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?

    Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017, which reflected ~18% YoY (year-over-year) growth. Xyrem’s net revenues over the first nine months of 2018 amounted to $1.0 billion—compared to $874.2 million in the same period in 2017, which reflects 18% YoY growth.

  • Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?
    Zacks7 days ago

    Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?

    We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.

  • These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
    Investor's Business Daily7 days ago

    These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece

    Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.

  • Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View
    Zacks10 days ago

    Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View

    Ligand (LGND) beats earnings and sales estimates in the third quarter of 2018 and raises full-year guidance for the second straight quarter.

  • Reuters11 days ago

    Novartis division Sandoz recalls one lot of blood pressure drug

    Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug. The drug is made by China's Zhejiang Huahai Pharmaceutical Co Ltd. Last month, the European Medicines Agency placed the firm under high supervision after a probable carcinogen was found in its blood pressure drug valsartan. A review was extended to other 'sartan' medicines, including candesartan, irbesartan, losartan, olmesartan and valsartan, after very low levels of a carcinogen was found in losartan made by Hetero Labs in India.

  • Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript
    Motley Fool11 days ago

    Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript

    LGND earnings call for the period ending September 30, 2018.

  • Mylan’s Major Drivers: Biosimilars and Asset Acquisitions
    Market Realist11 days ago

    Mylan’s Major Drivers: Biosimilars and Asset Acquisitions

    On June 4, the FDA issued a press release announcing regulatory approval for a biosimilar version of Amgen’s (AMGN) Neulasta and Mylan’s (MYL) Fulphilia. On September 20, the European Medicines Agency issued a press release announcing a positive opinion from the Committee for Medicinal Products for Human Use for Fulphila. According to Mylan’s investor presentation, Fulphila is targeting a global market opportunity worth more than $5.0 billion.

  • Here's Why PTC Therapeutics Dropped 18% in October
    Motley Fool12 days ago

    Here's Why PTC Therapeutics Dropped 18% in October

    The company's development-stage SMA treatment was supposed to knock out the market leader, but now it may be the one at risk of an upset.

  • This Rockville biotech is expanding to a new HQ. Here are the details.
    American City Business Journals12 days ago

    This Rockville biotech is expanding to a new HQ. Here are the details.

    The fast-growing company is consolidating into a larger headquarters in Rockville — not far from its current home.

  • Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes
    Zacks12 days ago

    Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes

    Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.

  • Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript
    Motley Fool13 days ago

    Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript

    IONS earnings call for the period ending September 30, 2018.